Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

SML1854

Sigma-Aldrich

Banoxantrone dihydrochloride

≥98% (HPLC)

Sinônimo(s):

1,4-Bis[[2-(dimethyloxidoamino)ethyl]amino]-5,8-dihydroxy-9,10-anthracenedione, AQ4N dihydrochloride

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C22H28N4O6 · 2HCl
Número CAS:
252979-56-9
Peso molecular:
517.40
Número MDL:
MFCD19690955
Código UNSPSC:
12352200
NACRES:
NA.77

Nível de qualidade

100

Ensaio

≥98% (HPLC)

forma

powder

condição de armazenamento

desiccated

cor

blue

solubilidade

H2O: 3 mg/mL, clear (warmed)

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

O=C1C2=C(C(NCC[N+](C)([O-])C)=CC=C2NCC[N+]([O-])(C)C)C(C3=C(O)C=CC(O)=C31)=O.[H]Cl.[H]Cl

InChI

1S/C22H28N4O6.2ClH/c1-25(2,31)11-9-23-13-5-6-14(24-10-12-26(3,4)32)18-17(13)21(29)19-15(27)7-8-16(28)20(19)22(18)30;;/h5-8,23-24,27-28H,9-12H2,1-4H3;2*1H

chave InChI

SBWCPHUXRZRTDP-UHFFFAOYSA-N

Aplicação

Banoxantrone dihydrochloride has been used as an organic ligand during a self-assembled metal-organic coordinated nanoparticle (Cu–OCNP/Lap) synthesis. It has also been used for the preparation of supramolecularly functionalized graphene oxide for hypoxia-activated chemotherapy of cancer.

Ações bioquímicas/fisiológicas

Banoxantrone (AQ4N) is a hypoxia-activated prodrug of topoisomerase II inhibitor AQ4 (Bioreductive AQ4 precursor).
Banoxantrone dihydrochloride enhances the anti-tumor effect caused by radiation.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Olivier Trédan et al.
Cancer research, 69(3), 940-947 (2009-01-30)
Hypoxic tumor cells are likely to be resistant to conventional chemotherapy, in large part because many anticancer drugs are unable to penetrate into poorly oxygenated tumor tissue. Here, we used quantitative immunofluorescence to study the distribution of mitoxantrone and AQ4N
Alshad S Lalani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 13(7), 2216-2225 (2007-04-04)
The antitumor activities and pharmacokinetics of the hypoxia-activated cytotoxin AQ4N and its metabolites were assessed in several preclinical models of pancreatic cancers. The cytotoxic effects of AQ4N prodrug and its bioreduced form, AQ4, were tested against multiple human tumor cell
Heather Nesbitt et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(7), 1797-1808 (2016-10-05)
Purpose: To understand the role of hypoxia in prostate tumor progression and to evaluate the ability of the novel unidirectional hypoxia-activated prodrug OCT1002 to enhance the antitumor effect of bicalutamide.Experimental Design: The effect of OCT1002 on prostate cancer cells (LNCaP
O P Friery et al.
British journal of cancer, 82(8), 1469-1473 (2000-04-26)
The ability of the bioreductive drugs AQ4N and tirapazamine to enhance the anti-tumour effect of cyclophosphamide was assessed in three murine tumour models. In male BDF mice implanted with the T50/80 mammary carcinoma, AQ4N (50-150 mg kg(-1)) in combination with

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica